A detailed history of Manufacturers Life Insurance Company, The transactions in Madrigal Pharmaceuticals, Inc. stock. As of the latest transaction made, Manufacturers Life Insurance Company, The holds 29,957 shares of MDGL stock, worth $9.24 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares
29,957
Previous 35,678 16.04%
Holding current value
$9.24 Million
Previous $10 Million 36.4%
% of portfolio
0.01%
Previous 0.01%

Shares

32 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024

SELL
$212.22 - $292.96 $1.21 Million - $1.68 Million
-5,721 Reduced 16.04%
29,957 $6.36 Million
Q2 2024

Aug 14, 2024

BUY
$193.33 - $291.99 $954,470 - $1.44 Million
4,937 Added 16.06%
35,678 $10 Million
Q1 2024

May 14, 2024

BUY
$171.37 - $283.23 $2.51 Million - $4.15 Million
14,662 Added 91.19%
30,741 $8.21 Million
Q4 2023

Feb 13, 2024

BUY
$120.4 - $237.13 $267,167 - $526,191
2,219 Added 16.01%
16,079 $3.72 Million
Q3 2023

Nov 15, 2023

BUY
$146.04 - $225.78 $1.19 Million - $1.84 Million
8,164 Added 143.33%
13,860 $2.02 Million
Q2 2023

Aug 11, 2023

BUY
$203.88 - $312.0 $144,754 - $221,520
710 Added 14.24%
5,696 $1.32 Million
Q1 2023

May 15, 2023

BUY
$231.06 - $307.08 $70,242 - $93,352
304 Added 6.1%
5,290 $1.28 Million
Q4 2022

Aug 11, 2023

SELL
$58.39 - $296.54 $6,189 - $31,433
-106 Reduced 2.08%
4,986 $1.45 Million
Q4 2022

Feb 13, 2023

SELL
$58.39 - $296.54 $6,189 - $31,433
-106 Reduced 2.08%
4,986 $1.45 Million
Q3 2022

Aug 11, 2023

SELL
$60.57 - $79.51 $6,178 - $8,110
-102 Reduced 1.96%
5,092 $330,000
Q3 2022

Nov 03, 2022

SELL
$60.57 - $79.51 $6,178 - $8,110
-102 Reduced 1.96%
5,092 $331,000
Q2 2022

Aug 11, 2023

BUY
$58.04 - $100.2 $12,420 - $21,442
214 Added 4.3%
5,194 $371,000
Q2 2022

Aug 15, 2022

BUY
$58.04 - $100.2 $12,420 - $21,442
214 Added 4.3%
5,194 $372,000
Q1 2022

Aug 11, 2023

SELL
$55.89 - $101.89 $17,325 - $31,585
-310 Reduced 5.86%
4,980 $488,000
Q1 2022

May 20, 2022

SELL
$55.89 - $101.89 $67,235 - $122,573
-1,203 Reduced 19.46%
4,980 $489,000
Q4 2021

Feb 16, 2022

BUY
$72.34 - $95.09 $4,051 - $5,325
56 Added 0.91%
6,183 $524,000
Q3 2021

Nov 12, 2021

SELL
$78.35 - $105.02 $36,041 - $48,309
-460 Reduced 6.98%
6,127 $489,000
Q2 2021

Aug 12, 2021

BUY
$97.2 - $137.59 $140,940 - $199,505
1,450 Added 28.23%
6,587 $642,000
Q1 2021

May 03, 2021

SELL
$108.54 - $125.2 $29,305 - $33,804
-270 Reduced 4.99%
5,137 $601,000
Q4 2020

Feb 12, 2021

BUY
$110.06 - $133.7 $14,417 - $17,514
131 Added 2.48%
5,407 $601,000
Q3 2020

Nov 09, 2020

SELL
$99.78 - $124.21 $9,279 - $11,551
-93 Reduced 1.73%
5,276 $626,000
Q2 2020

Aug 10, 2020

SELL
$60.13 - $125.71 $15,032 - $31,427
-250 Reduced 4.45%
5,369 $552,000
Q1 2020

May 15, 2020

BUY
$66.76 - $93.49 $47,533 - $66,564
712 Added 14.51%
5,619 $375,000
Q4 2019

Feb 14, 2020

SELL
$84.28 - $118.5 $16,097 - $22,633
-191 Reduced 3.75%
4,907 $447,000
Q2 2019

Aug 14, 2019

BUY
$91.13 - $142.5 $36,725 - $57,427
403 Added 8.58%
5,098 $534,000
Q1 2019

May 13, 2019

BUY
$103.48 - $143.84 $47,600 - $66,166
460 Added 10.86%
4,695 $588,000
Q4 2018

Feb 14, 2019

SELL
$94.77 - $215.54 $39,424 - $89,664
-416 Reduced 8.94%
4,235 $477,000
Q3 2018

Nov 14, 2018

BUY
$207.3 - $300.31 $27,985 - $40,541
135 Added 2.99%
4,651 $996,000
Q2 2018

Aug 14, 2018

BUY
$101.55 - $313.9 $76,264 - $235,738
751 Added 19.95%
4,516 $1.26 Million
Q1 2018

May 15, 2018

BUY
$93.35 - $149.04 $19,790 - $31,596
212 Added 5.97%
3,765 $439,000
Q4 2017

Feb 08, 2018

BUY
$39.35 - $97.37 $55,050 - $136,220
1,399 Added 64.95%
3,553 $326,000
Q3 2017

Nov 14, 2017

BUY
$15.48 - $46.19 $33,343 - $99,493
2,154
2,154 $96,000

Others Institutions Holding MDGL

About MADRIGAL PHARMACEUTICALS, INC.


  • Ticker MDGL
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 17,103,400
  • Market Cap $5.28B
  • Description
  • Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. Its lead product candidate is resmetirom, a liver-directed selective thyroid hormone receptor-ß agonist, which is in Phase III c...
More about MDGL
Track This Portfolio

Track Manufacturers Life Insurance Company, The Portfolio

Follow Manufacturers Life Insurance Company, The and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Manufacturers Life Insurance Company, The, based on Form 13F filings with the SEC.

News

Stay updated on Manufacturers Life Insurance Company, The with notifications on news.